CASP1 and polycystic ovary syndrome: In comparison with the PCOS-IR group, the PCOS-IR+GPR120 agonist, PCOS-IR+LrB (40 mg/kg), and PCOS-IR+LrB (20 mg/kg) groups presented significant decreases in NLRP3 and Caspase-1 (Figure 11A,F), while the PCOS-IR+LrB (10 mg/kg) group presented significant decreases in NLRP3 and caspase-1 (Figure 11A,F).